COMP <GO>
LFVN vs ABBV // GROSS PROFIT MARGIN
Lifevantage Corporation (Delaware) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LFVN 8
— ABBV 5
▲ GROSS PROFIT MARGIN LEADER: LFVN
LAST: $5.88 (+0.17%) • MKT CAP: $73.9M
gross-margins
80.40%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFVN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFVN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 80.40% | 70.20% | +10.20 | LFVN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | 29.00% | +0.20 | LFVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.5x | 33.3x | -27.80 | LFVN | /valuation <GO> |
| Free Cash Flow Yield | 14.22% | 3.47% | +10.75 | LFVN | /fcf-yield <GO> |
| Operating Margin | 5.30% | 24.60% | -19.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 4.30% | 6.90% | -2.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 8.60% | +5.60 | LFVN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.80% | 2.27% | +0.53 | LFVN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | 5.33 | -1.35 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | LFVN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.6 | 65.1 | -15.48 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | 113.1x | -106.80 | LFVN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $73.9M | $513.86B | -$513.79B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFVN REV | ABBV REV | LFVN GROSS % | ABBV GROSS % | LFVN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.5M | $61.16B | 80.4% | 70.2% | $10.5M | $17.82B |
| FY 2024 | $200.2M | $56.33B | 79.3% | 70.0% | $10.0M | $17.83B |
| FY 2023 | $213.4M | $54.32B | — | — | $6.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFVN // BETA —
ABBV // BETA 1.15